RPS6KB1 and neoplasm: Recent studies have reported that the gain of function is the central role of RPS6KB1 in resistance to tyrosine kinase (TKI) in lung cancer, and its specific inhibitor PF-4708671 shows synergistic effect to enhance TKIs efficacy to suppress tumor growth in vivo [33].